Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

Complications of Diabetes Mellitus

Complications of Diabetes Mellitus

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to insulin deficiency, resistance, or both. Prolonged hyperglycemia disrupts metabolic homeostasis and leads to acute and chronic complications.Acute ComplicationsAcute complications result from sudden metabolic imbalance.Diabetic ketoacidosis (DKA) mainly appears in type 1 diabetes but may also develop in type 2 diabetes, particularly under extreme stress. It arises from severe insulin deficiency,...

Diabetic Nephropathy

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...

Diabetic Retinopathy

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Acute responses of hepatic fat content to consuming fat, glucose and fructose alone and in combination in non-obese non-diabetic individuals with non-alcoholic fatty liver disease.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2021

Same author

High strength, biodegradable and cytocompatible alpha tricalcium phosphate-iron composites for temporal reduction of bone fractures.

Acta biomaterialia·2018

Same author

Trefoil factor family (TFF) proteins as potential serum biomarkers in patients with metastatic colorectal cancer.

Neoplasma·2015

Same author

[Wilsons disease].

Vnitrni lekarstvi·2013

Same author

[Hepatic cein catheterisation - selected assessment aspects].

Vnitrni lekarstvi·2013

Same author

Anemia as a predictor of response to antiviral therapy in chronic hepatitis C.

Bratislavske lekarske listy·2013

Search research articles

Related Experiment Video

Updated: May 9, 2026

Hepatic Glucose Production, Ureagenesis, and Lipolysis Quantified using the Perfused Mouse Liver Model

Hepatic Glucose Production, Ureagenesis, and Lipolysis Quantified using the Perfused Mouse Liver Model

Published on: October 6, 2023

[Liver disorders in diabetic patients].

R Brůha¹, K Dvořák, J Petrtýl

¹IV. interní klinika 1. lékařské fakulty UK a VFVN Praha. bruha@cesnet.cz

Vnitrni Lekarstvi

|August 6, 2013

Summary

Diabetes and liver disease are closely linked, with each condition increasing the risk of the other. Managing diabetes and lifestyle is key for liver health, especially for nonalcoholic steatohepatitis.

Area of Science:

Hepatology
Endocrinology
Metabolic Syndrome

Background:

Diabetes mellitus and liver disorders share a bidirectional relationship, increasing the prevalence and risk of developing each condition.
Diabetes is a leading cause of chronic liver disease in developed nations, encompassing conditions from simple steatosis to cirrhosis and hepatocellular carcinoma.
Nonalcoholic fatty liver disease (NAFLD) is a common manifestation of metabolic syndrome, characterized by insulin resistance, obesity, dyslipidemia, and hypertension.

Purpose of the Study:

To elucidate the complex interplay between diabetes and various liver disorders.
To highlight the spectrum of liver conditions associated with diabetes, including nonalcoholic steatohepatitis (NASH).
To discuss the current understanding and management strategies for NAFLD and its progression.

More Related Videos

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature

Published on: January 24, 2025

Related Experiment Videos

Last Updated: May 9, 2026

Hepatic Glucose Production, Ureagenesis, and Lipolysis Quantified using the Perfused Mouse Liver Model

Hepatic Glucose Production, Ureagenesis, and Lipolysis Quantified using the Perfused Mouse Liver Model

Published on: October 6, 2023

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature

Published on: January 24, 2025

Main Methods:

Review of existing literature on the relationship between diabetes and liver disease.
Analysis of the pathological progression of nonalcoholic steatosis to steatohepatitis and fibrosis.
Examination of the components of metabolic syndrome and their association with liver manifestations.

Main Results:

Diabetic patients exhibit a higher incidence of liver disorders, while liver disease patients have an increased risk of developing diabetes.
Nonalcoholic steatohepatitis (NASH) is a significant liver manifestation of metabolic syndrome, linked to insulin resistance and other metabolic abnormalities.
While steatosis is benign, inflammatory progression to steatohepatitis and fibrosis represents unfavorable liver disorder development.

Conclusions:

Effective management of diabetes and associated metabolic conditions is crucial for mitigating liver disease progression.
Lifestyle modifications, including weight reduction and treatment of dyslipidemia, are fundamental in managing nonalcoholic steatohepatitis.
Current evidence does not support a significant role for "hepatoprotective" agents in the treatment of steatohepatitis.